238 related articles for article (PubMed ID: 32687855)
1. Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
Mehravar M; Roshandel E; Salimi M; Chegeni R; Gholizadeh M; Mohammadi MH; Hajifathali A
Immunol Lett; 2020 Oct; 226():71-82. PubMed ID: 32687855
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma.
Hong L; Zhang C; Jiang Y; Liu H; Huang H; Guo D
Future Oncol; 2020 Jun; 16(16):1125-1136. PubMed ID: 32338048
[TBL] [Abstract][Full Text] [Related]
4. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
5. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
6. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
8. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
9. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
10. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
[TBL] [Abstract][Full Text] [Related]
12. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
Mills EM; Barlow VL; Luk LYP; Tsai YH
Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
Ma X; Zhu Q; Chen Y; Liu YG
Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
Muramoto T; Iriki H; Watanabe J; Kawata T
Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
Zhang X; Wang L; Liu M; Li D
Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
[TBL] [Abstract][Full Text] [Related]
19. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
Tao Y; Yi K; Hu H; Shao D; Li M
J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
Jacinto FV; Link W; Ferreira BI
J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
